GTAEXS617 + fulvestrant

GTAEXS617 + fulvestrant is a combination therapy currently in early clinical development for the treatment of advanced solid tumors, including hormone receptor-positive, HER2-negative breast cancer and other malignancies. GTAEXS617 is an orally bioavailable, highly selective, non-covalent small molecule inhibitor of cyclin-dependent kinase 7 (CDK7), designed using artificial intelligence for enhanced potency, selectivity, and safety. Fulvestrant is a selective estrogen receptor degrader (SERD) that binds, blocks, and accelerates the degradation of the estrogen receptor. The rationale for combining these agents is to simultaneously block estrogen signaling (fulvestrant) and cell cycle transcription control (GTAEXS617) for improved antitumor activity in cancers driven by hormone and cyclin-dependent pathways. Development is led by Exscientia and GT Apeiron, with GTAEXS617 in Phase 1/2 “ELUCIDATE” clinical trials as a monotherapy and in combination with standard of care therapies, including fulvestrant for HR+/HER2- breast cancer[1][2][3][4][5][6][7][8].